Zeev Weiss

Zeev has over 20 years of broad and extensive biopharmaceuticals industry experience in strategic, operational, and corporate development in the emerging and established healthcare industry. Until 2017, Zeev served as the CEO and formerly as Executive VP Commercial Operations of Intec Pharma (NASDAQ: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill® platform technology. Zeev successfully led Intec’s IPO on NASDAQ as well as multiple collaboration agreements with global leading pharmaceutical companies. Zeev also had a central role in leading Intec from its very early stage into the late clinical-stage, including raising substantial funds, obtaining non-dilutive grants, progressing pre-clinical and clinical development, regulatory and IP activities.

Prior to Intec, Zeev was Head of Life Sciences Strategic Consulting at PricewaterhouseCoopers, Israel. At PwC, Zeev led numerous corporate developments, business development, strategic planning, and corporate finance consulting engagements with various healthcare companies.

Zeev holds a BA in accounting and is a certified public accountant. He also earned a B.Sc in Biology and has completed M.Sc. in Neuro-Biochemistry studies from Tel Aviv University, Israel.